Information Provided By: 
Fly News Breaks for September 17, 2019
XLRN
Sep 17, 2019 | 06:09 EDT
Citi analyst Yigal Nochomovitz lowered his price target for Acceleron Pharma to $52 from $61 after the company discontinued ACE-083 in facioscapulohumeral muscular dystrophy following failure in Phase 2 to improve functional endpoints versus placebo. The analyst, however, says FSHD failure was in-line with his expectations as he had only modeled a 10% probability of success. He keeps a Buy rating on Acceleron shares.
News For XLRN From the Last 2 Days
There are no results for your query XLRN
